Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MedImmune (MEDI) raised its second quarter EPS estimate to $0.02-$0.05 from $0.00-$0.02 to account for continued
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury